

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)**

Thursday, March 9, 2017

**145th Meeting of the Vaccines and Related Biological Products Advisory Committee
NIH Conference Center
5635 Fishers Lane, Rockville, MD 20850**

Live Webcast: <https://videocast.nih.gov>

DRAFT AGENDA

Time	Presentation/ Presenter
8:30 A.M.	Call to Order and Opening Remarks Introduction of Committee Kathryn Edwards, M.D. Chair, VRBPAC Conflict of Interest Statement Prabhakara Atreya, Ph.D. Acting Designated Federal Officer VRBPAC, FDA

Topic: Strain Selection for the Influenza Virus Vaccines for the 2017-2018 Influenza Season

Time	Presentation/ Presenter
8:45 a.m.	Introduction Anissa Cheung, M.Sc. Regulatory Coordinator Division of Viral Products Office of Vaccines Research and Review CBER/FDA
8:55 a.m.	U.S. Surveillance Lisa Grohskopf, M.D., M.P.H. CAPT. USPHS Associate Chief for Policy & Liaison Activities, Epidemiology & Prevention Branch, Influenza Division Centers for Disease Control and Prevention

Time	Presentation/ Presenter
9:20 a.m.	<p>World Surveillance/Virus Characterization</p> <p>Jacqueline Katz, Ph.D. Deputy Director, Influenza Division and Director, WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention</p>
10:30 a.m.	<p>BREAK</p>
10:45 a.m.	<p>DoD Vaccine Effectiveness Report</p> <p>Michael Cooper, Ph.D. CAPT, USPHS Respiratory Infection Surveillance Global Emerging Infections Section, Armed Armed Forces Health Surveillance Branch Silver Spring, MD</p>
11:10 a.m.	<p>Candidate Vaccine Strains& Potency Reagents</p> <p>Manju Joshi, Ph.D. Lead Biologist Division of Biological Standards & Quality Office of Compliance and Biologics Quality CBER/FDA</p>
11:30 a.m.	<p>Comments from Manufacturers</p> <p>Beverly Taylor, Ph.D. Head of Influenza Scientific Affairs and Pandemic Readiness Seqirus Vaccines Limited United Kingdom</p>
11:55 a.m.	<p>LUNCH</p>
12:50 p.m.	<p>Open Public Hearing</p>
1:50 p.m.	<p>Committee Discussion, Voting, and Recommendations</p>
3:00 p.m.	<p>Adjournment</p>